Special Issue

Heart Disease in Cancer Patients and Cancer in Patients with Heart Disease: How to Manage This Double Problem?

Message from the Guest Editor

Dear colleagues, As life expectancy increases, more patients will suffer from both heart disease and malignancy, either simultaneously or consecutively.

- Both conditions have common risk factors, such as ageing, obesity, and the use of tobacco.
- Furthermore, treatment of malignancy can be responsible for heart disease.
- Difficult situations can also arise in patients needing antithrombotic medication after PCI, who develop cancer in the first year after the procedure, or who suffer from chronic hematologic disease.
- A very serious—but relatively rare—condition is endocarditis caused by Streptococcus gallolyticus and enterococci, which is often associated with colonic neoplasia.

Several questions for cardiologists and oncologists: How can I ensure that a cancer patient receives the optimal oncological treatment, especially when cardiotoxic treatment is involved? How can I anticipate and treat these patients most accurately? What is the best option for any cancer patient who is confronted with concomitant or subsequent heart disease? Any contribution could answer these questions is welcome.

Guest Editor

Dr. Wilhelm P. Mistiaen

Faculty of Medicine and Health Sciences, University of Antwerp, 2000 Antwerp, Belgium

Deadline for manuscript submissions

closed (15 April 2020)



Healthcare

an Open Access Journal by MDPI

Impact Factor 2.7
CiteScore 4.7
Indexed in PubMed



mdpi.com/si/29868

Healthcare
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
healthcare@mdpi.com

mdpi.com/journal/ healthcare





Healthcare

an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Healthcare is an international, peerreviewed, open access, multidisciplinary journal. Original research articles, short communications, review articles, and symposium highlights are welcomed.

Healthcare hopes to influence global health and disease aspects, and hopes to gain high visibility and acceptance by the scientific and healthcare community and will dedicate itself to covering special and specific topics in special

We would be pleased to welcome you as one of our authors.

Editor-in-Chief

issues.

Prof. Dr. Lorraine S. Evangelista

Louise Herrington School of Nursing, Baylor University, Dallas, TX 75246-1754, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE and SSCI (Web of Science), PubMed, PMC, and other databases.

Journal Rank:

JCR - Q2 (Health Policy and Services) / CiteScore - Q1 (Leadership and Management)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

